Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering

Series D warrants are immediately exercisable and expire five years after their initial issuance.

Rhea-AI Summary

Sunshine Biopharma (NASDAQ:SBFM) closed its public offering, raising approximately $6.0 million in gross proceeds before placement agent fees and other offering expenses.

The offering comprised 10,909,082 Common Units or Pre-Funded Units, priced at $0.55 or $0.54999 each, respectively. Each unit included one common share or one Pre-Funded Warrant, plus two Series D Warrants. Each Series D Warrant initially permits purchase of one common share at $0.66. Full cash exercise of the Series D Warrants would provide approximately $14.4 million in additional gross proceeds. Sunshine Biopharma expects to use net proceeds for general corporate purposes and working capital.

2 points · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointClosed offering raised approximately $6.0 million in gross proceeds before fees and offering expenses. 3.6× market cap
• Minor point. Forward-looking: it has not happened yet and may not happen.Series D Warrants could provide approximately $14.4 million in additional gross proceeds if fully exercised for cash.

Negative

• Major point10,909,082 units at $0.55 or $0.54999 issue common shares or Pre-Funded Warrants, diluting holders.
• Minor point. Forward-looking: it has not happened yet and may not happen.Two Series D Warrants per unit, initially exercisable at $0.66 per share, create potential additional dilution.
• Minor pointPlacement agent fees and other offering expenses reduce the proceeds available to the company.

News Explained

The completed offering placed common shares or pre-funded warrants, plus two Series D warrants per unit; issued shares and later warrant exercises can increase the share count and reduce existing holders’ ownership percentages.

Key Figures

Gross proceeds: Approximately $6.0 million Potential warrant proceeds: Approximately $14.4 million Units offered: 10,909,082 Common Units or Pre-Funded Units +4 more

Gross proceeds

Approximately $6.0 million

At closing, before placement agent fees and other offering expenses

Potential warrant proceeds

Approximately $14.4 million

Additional gross proceeds only if Series D Warrants are fully exercised for cash

Units offered

10,909,082 Common Units or Pre-Funded Units

Public offering

Unit price

$0.55 per Common Unit; $0.54999 per Pre-Funded Unit

Public offering price

Series D Warrant exercise price

$0.66 per share

Initial exercise price

Series D Warrants per unit

2 warrants

Each warrant is for one share of Common Stock

Series D Warrant term

5 years

Expires five years after initial issuance

Previous Offering Reports

1 past event · Latest: Oct 08

Same Type 1 event

1. Oct 08

   Offering pricing

   24h Move

   -38.6%

   The same transaction was priced with $6.0 million expected gross proceeds and Series D warrants.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pre-funded warrant, best efforts, registration statement, prospectus

4 terms

pre-funded warrant financial

"one (1) Pre-Funded Warrant"

A pre-funded warrant is a financial instrument that gives the holder the right to buy shares of a company's stock at a set price, with most of the purchase cost already paid upfront. It functions like a nearly fully paid option, allowing investors to secure shares quickly while minimizing the amount of additional money they need to invest later. This helps investors gain ownership rights efficiently, often used to avoid certain regulatory restrictions or to prepare for future stock purchases.

best efforts financial

"made on a reasonable best efforts basis"

A contractual promise to make a genuine, diligent effort to achieve a specified result without guaranteeing the outcome. For investors, it means a counterparty (for example, an underwriter or service provider) must work hard to deliver an outcome but is not legally required to produce a specific result, so the investor retains some risk; think of it like hiring someone to try their hardest to sell your house rather than promising they will sell it.

registration statement regulatory

"A registration statement on Form S-1"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

prospectus regulatory

"A final prospectus describing the terms of the offering"

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FORT LAUDERDALE, FL / ACCESS Newswire / October 9, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology and antivirals, today announced the closing of its previously announced public offering made on a reasonable best efforts basis with gross proceeds to the Company of approximately $6.0 million, before deducting placement agent fees and other offering expenses payable by the Company.

The offering consisted of 10,909,082 Common Units (or Pre-Funded Units), each consisting of (i) one (1) share of Common Stock or one (1) Pre-Funded Warrant and (ii) two (2) Series D Warrants to purchase one (1) share of Common Stock per warrant at an initial exercise price of $0.66. The public offering price per Common Unit was $0.55 (or $0.54999 per Pre-Funded Unit, which is equal to the public offering price per Common Unit sold in the offering minus an exercise price of $0.00001 per share under the Pre-Funded Warrants). The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until exercised in full. The Series D Warrants are exercisable immediately and expire five years after the initial issuance date. The exercise price and number of shares issuable under the Series D Warrants are subject to adjustment as described in more detail in the final prospectus filed in connection with the offering.

Gross proceeds to the Company were approximately $6.0 million. The potential additional gross proceeds to the Company from the Series D Warrants, if fully-exercised on a cash basis, will be approximately $14.4 million. No assurance can be given that any of warrants will be exercised. The Company expects to use the net proceeds from the offering for general corporate purposes and working capital.

Aegis Capital Corp. acted as the exclusive placement agent for the offering. Sichenzia Ross Ference Carmel LLP acted as counsel to the Company. Kaufman & Canoles, P.C. acted as counsel to Aegis Capital Corp.

A registration statement on Form S-1 (No. 333-299274) previously filed with the U.S. Securities and Exchange Commission (the "SEC") on October 2, 2026 was declared effective by the SEC on October 7, 2026. The offering was made only by means of a prospectus. A final prospectus describing the terms of the offering has been filed with the SEC and is available on the SEC's website at www.sec.gov. Electronic copies of the final prospectus may be obtained by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010. Before investing in this offering, interested parties should read, in its entirety, the prospectus, which provides more information about the Company and the offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Sunshine Biopharma Inc.

Sunshine Biopharma currently markets 61 generic prescription drugs in Canada, with approximately 11 additional launches planned for the remainder of 2026. The Company is also advancing two proprietary drug development programs:

• K1.1 mRNA, an mRNA‑Lipid Nanoparticle therapeutic candidate targeting liver cancer.
• PLpro protease inhibitor, a small‑molecule antiviral candidate for SARS‑related coronavirus infections.

Additional information is available at www.sunshinebiopharma.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company's product development and business prospects, the use of proceeds from the offering, and the exercise of any warrants, can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans, including the risk factors described in the Company's documents filed with the Securities and Exchange Commission. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned as a result of these risks. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Camille Sebaaly, CFO
Direct Line: 514‑814‑0464
camille.sebaaly@sunshinebiopharma.com

SOURCE: Sunshine Biopharma Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did Sunshine Biopharma raise in its public offering?

Sunshine Biopharma raised approximately $6.0 million in gross proceeds, before placement agent fees and other offering expenses. Full cash exercise of the Series D Warrants would provide approximately $14.4 million in additional gross proceeds; that amount is conditional, not funding already received.

What are the exercise terms of Sunshine Biopharma's offering warrants?

Pre-Funded Warrants are immediately exercisable at $0.00001 per share and remain exercisable until exercised in full. Series D Warrants are immediately exercisable at an initial $0.66 per share and expire five years after initial issuance. Their exercise price and the number of shares issuable are subject to adjustment.